Sugi Predict
/ Targets
/ MRE11
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MRE11 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency |
PHASE2/PHASE3 | RECRUITING |
| Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) |
PHASE2 | COMPLETED |
| Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation |
PHASE2 | UNKNOWN |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers |
PHASE2 | COMPLETED |
| A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. |
PHASE2 | WITHDRAWN |
| Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers |
PHASE2 | WITHDRAWN |
| Olaparib In Metastatic Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) |
PHASE2 | UNKNOWN |
| Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy |
PHASE2 | RECRUITING |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations |
PHASE2 | COMPLETED |
| Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations |
PHASE2 | COMPLETED |
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
PHASE2 | RECRUITING |
| Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer |
PHASE2 | WITHDRAWN |
| A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations |
PHASE1 | WITHDRAWN |
| Chromosomal Translocations in Chandigarh Police |
nan | COMPLETED |
| Genetics of Prostate Cancer in Young Patients |
nan | COMPLETED |
| INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations |
nan | RECRUITING |
| Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a MRE11 binder may also engage these)